Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

abstract：:Non-motor symptoms may considerably reduce parkinsonian quality of life, particularly in advanced stages of the disease. Autonomic features, such as seborrhoea, hyperhidrosis, orthostatic hypotension, excessive salivation, bladder dysfunction and GI disturbances, and neuropsychiatric symptoms, such as depression, slee...

journal_title：Expert opinion on pharmacotherapy

authors： Müller T

更新日期：2002-04-01 00:00:00

abstract：INTRODUCTION:Hepatocellular carcinoma (HCC) is a frequent and severe complication of cirrhosis. Most HCC patients initially present with or progress to advanced stage disease and require systemic treatment. As hypervascularization is a major characteristic of HCC, antiangiogenic drugs have been tested. Areas covered: I...

journal_title：Expert opinion on pharmacotherapy

authors： Raoul JL,Gilabert M,Adhoute X,Edeline J

更新日期：2017-10-01 00:00:00

abstract：INTRODUCTION:Over the past decade, treatment options for men with metastatic castration-resistant prostate cancer (CRPC) have expanded with the addition of abiraterone acetate (AA), enzalutamide, sipuleucel-T, radium-223, docetaxel and cabazitaxel. The optimal sequencing of therapies in the context of efficacy and know...

journal_title：Expert opinion on pharmacotherapy

authors： Zhang T,Zhu J,George DJ,Armstrong AJ

更新日期：2015-03-01 00:00:00

abstract：INTRODUCTION:Patisiran and inotersen are two therapies approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, a rapidly progressive disease with a substantial clinical burden. This analysis indirectly compares the efficacy of patisiran and inotersen on neuropathy and qu...

journal_title：Expert opinion on pharmacotherapy

authors： Gorevic P,Franklin J,Chen J,Sajeev G,Wang JCH,Lin H

更新日期：2021-01-01 00:00:00

abstract：INTRODUCTION:Allergic rhinitis (AR) can be challenging to treat. For many patients, current therapies (including multiple therapies) provide insufficient symptom relief. There is, therefore, a clear unmet medical need for a new and more effective AR treatment option. MP29-02 ( Dymista ) is a novel intranasal formulatio...

journal_title：Expert opinion on pharmacotherapy

authors： Bernstein JA

更新日期：2013-10-01 00:00:00

abstract：INTRODUCTION:Migraine is a common and highly disabling neurological disorder whose acute treatment remains problematic and unsatisfactory in a high percentage of cases. Consequently, there remains a need for new symptomatic therapies that can be easily handled by patients (i.e. by oral administration). AREAS COVERED:T...

journal_title：Expert opinion on pharmacotherapy

authors： Martelletti P,Giamberardino MA

更新日期：2019-02-01 00:00:00

abstract：:Therapy of hepatitis C virus (HCV) infection may prevent progression to cirrhosis, hepatocellular carcinoma and end-stage liver disease. The cornerstone of treatment has long been standard IFN-alpha, the use of which was associated with a sustained biochemical and viral response in only a small proportion of patients....

journal_title：Expert opinion on pharmacotherapy

authors： Toniutto P,Fabris C,Pirisi M

更新日期：2006-10-01 00:00:00

abstract：:The purpose of this review is to critically review the current literature on olanzapine with an emphasis on emergent themes and key findings in the use of this agent for the treatment of mood disorders and schizophrenia. New information continues to emerge on the impact of olanzapine on schizophrenia and on aspects of...

journal_title：Expert opinion on pharmacotherapy

authors： Buckley PF

更新日期：2005-10-01 00:00:00

abstract：INTRODUCTION:Peripheral artery disease (PAD) is a prevalent but underdiagnosed manifestation of atherosclerosis that has a worse prognosis than coronary artery disease. Patients with PAD are at heightened risk of both systemic cardiovascular adverse events and limb-related morbidity. There is insufficient awareness of ...

journal_title：Expert opinion on pharmacotherapy

authors： Essa H,Torella F,Lip GYH

更新日期：2020-09-01 00:00:00

abstract：INTRODUCTION:Multiple myeloma is a disease predominately affecting older adults. Pivotal to treating older adults is understanding their physiologic differences compared to younger subjects and how the complexity of therapies has an impact upon this patient population. AREAS COVERED:Herein, the authors address the eff...

journal_title：Expert opinion on pharmacotherapy

authors： Dempsey JL,Johns A,Rosko AE,Lazarus HM

更新日期：2019-05-01 00:00:00

abstract：INTRODUCTION:Varicella zoster virus is a highly contagious virus that causes a primary infection known as varicella (chickenpox) that may reactivate years later to cause herpes zoster (HZ or shingles). After shingles heal, patients may develop post-herpetic neuralgia (PHN), neuropathic pain syndrome that can cause sign...

journal_title：Expert opinion on pharmacotherapy

authors： Kim SR,Khan F,Ramirez-Fort MK,Downing C,Tyring SK

更新日期：2014-01-01 00:00:00

abstract：:Diabetes mellitus is the most common cause of blindness among working-age adults, with a prevalence of 7 - 8% of adults in the USA, and is one of the most common causes of renal failure requiring kidney transplant and the most common cause of non-traumatic lower limb amputation in developed nations [1] . The role of t...

journal_title：Expert opinion on pharmacotherapy

authors： Danis RP,Sheetz MJ

更新日期：2009-12-01 00:00:00

abstract：INTRODUCTION:Intravenous (I.V.) morphine administered through a patient-controlled system currently represents the gold standard treatment for moderate to severe acute postoperative pain. To fix the limitations showed by the available I.V. patient-controlled analgesia (PCA) systems that may restrict its use in the clin...

journal_title：Expert opinion on pharmacotherapy

authors： Fanelli A,Sorella MC,Chelly JE

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Women are more vulnerable to the development of major depressive disorder (MDD) than men. Although several epidemiological studies have investigated the association between antidepressants and the risk of developing cancer, different methodologies were applied and as a result most of the results were incon...

journal_title：Expert opinion on pharmacotherapy

authors： Pae CU

更新日期：2012-02-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Current therapy for Parkinson's disease (PD) is primarily directed at reversing the motor symptoms that are the consequence of dopamine deficiency and includes levodopa, dopamine agonists and monoamine oxidase (MAO) B inhibitors. New drugs offering both dopaminergic and non-dopaminergic actions ...

journal_title：Expert opinion on pharmacotherapy

authors： Schapira AH

更新日期：2010-09-01 00:00:00

abstract：INTRODUCTION:Diabetic foot ulcers, especially when they become infected, are a leading cause of morbidity and may lead to severe consequences, such as amputation. Optimal treatment of these diabetic foot problems usually requires a multidisciplinary approach, typically including wound debridement, pressure off-loading,...

journal_title：Expert opinion on pharmacotherapy

authors： Abbas M,Uçkay I,Lipsky BA

更新日期：2015-04-01 00:00:00

abstract：:Synovitis is a painful and, occasionally, disabling disease. Patients with synovitis, especially new onset synovitis, should be referred to a rheumatologist urgently so that they can be assed and treated as quickly as possible. Clinical assessment and investigations are required to help differentiate between transient...

journal_title：Expert opinion on pharmacotherapy

authors： Sokoll KB,Helliwell P

更新日期：2006-01-01 00:00:00

abstract：:Cronkhite-Canada syndrome (CCS) is a rare, non-inherited gastrointestinal polyposis syndrome associated with characteristic ectodermal abnormalities. A number of potentially life-threatening complications including malnutrition, gastrointestinal bleeding and infection may occur in affected patients and CCS is fatal in...

journal_title：Expert opinion on pharmacotherapy

authors： Ward EM,Wolfsen HC

更新日期：2003-03-01 00:00:00

abstract：INTRODUCTION:Chronic obstructive pulmonary disease (COPD) is a complex respiratory disorder, whose medical and socioeconomic burden as one of the main causes of morbidity and mortality is increasing worldwide. COPD pathophysiology includes chronic airway/lung inflammation and progressive airflow limitation. Therefore, ...

journal_title：Expert opinion on pharmacotherapy

authors： Pelaia G,Muzzio CC,Vatrella A,Maselli R,Magnoni MS,Rizzi A

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Aripiprazole long acting once-monthly (AOM) is approved for the treatment of schizophrenia in adults. Despite recent evidence of AOM efficacy in the acute treatment of schizophrenia, it is recommended that AOM should be started once the acute symptoms are controlled and patients are stabilized. However, th...

journal_title：Expert opinion on pharmacotherapy

authors： Amodeo G,Candiracci C,Capecci I,De Filippis S,Giuliani S,Guerani G,Tomasetti C,Villari V,Fagiolini A

更新日期：2016-11-01 00:00:00

abstract：INTRODUCTION:Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist (LABA) are the preferred long-term treatment for adults and adolescents with symptomatic asthma. Additional drugs include leukotriene-receptor antagonists, slow-release theophylline and the long-acting muscarini...

journal_title：Expert opinion on pharmacotherapy

authors： Thomson NC

更新日期：2017-02-01 00:00:00

abstract：:A number of medicine selection methods have been used worldwide for formulary purposes. In Northern Ireland, integrated medicines management is being developed, and related projects have been carried out. This paper deals with the description of the STEPS (Safe Therapeutic Economic Pharmaceutical Selection) programme....

journal_title：Expert opinion on pharmacotherapy

authors： Scott M,Timoney M,Mairs J,Crealey G,Al Abaddi I,Brenninkmeijer R,Janknegt R,McElnay J

更新日期：2007-10-01 00:00:00

abstract：:The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 µg daily subcutaneous) (ABL) vs placebo during 18 months, in postmenopausal osteoporosis. Teriparatide (20 µg daily subcutaneous) (TPD) was used as an open label active comparator...

journal_title：Expert opinion on pharmacotherapy

authors： Reginster JY,Al Daghri NM,Bruyere O

更新日期：2017-12-01 00:00:00

abstract：INTRODUCTION:Overactive bladder (OAB) is a common condition that has a profound impact on an individual's overall health and quality of life. Muscarinic receptor antagonists are the mainstay of oral pharmacotherapy for OAB. While all of the medications in this class are significantly more effective than placebo, they a...

journal_title：Expert opinion on pharmacotherapy

authors： Gomelsky A,Dmochowski RR

更新日期：2012-06-01 00:00:00

abstract：OBJECTIVE:The intent of this pooled analysis was to determine the relationship between baseline depression symptom severity and treatment response for escitalopram compared to that for other pooled antidepressant medications (citalopram, duloxetine, fluoxetine, paroxetine, sertraline and venlafaxine). METHODS:Data wer...

journal_title：Expert opinion on pharmacotherapy

authors： Kilts CD,Wade AG,Andersen HF,Schlaepfer TE

更新日期：2009-04-01 00:00:00

abstract：BACKGROUND:Incomplete remission and treatment resistance are common even in first-episode psychosis patients. OBJECTIVE:The aim of this review was to provide an overview of the available interventions and treatment pathways for the management of incomplete remission and treatment resistance in first-episode psychosis....

journal_title：Expert opinion on pharmacotherapy

authors： Lambert M,Naber D,Huber CG

更新日期：2008-08-01 00:00:00

abstract：INTRODUCTION:Ziconotide is an N-type calcium channel antagonist to treat chronic pain that is delivered intrathecally. It is the only intrathecal, FDA-approved, non-opioid analgesic and is recommended as first-line therapy. Despite these advantages, a small therapeutic window limits ziconotide's clinical utility, with ...

journal_title：Expert opinion on pharmacotherapy

authors： Pope JE,Deer TR

更新日期：2013-05-01 00:00:00

abstract：INTRODUCTION:Lysosomal storage disorders (LSDs) are clinically heterogeneous disorders that result primarily from lysosomal accumulation of macromolecules in various tissues. LSDs are always progressive, and often lead to severe symptoms and premature death. The identification of the underlying genetic and enzymatic de...

journal_title：Expert opinion on pharmacotherapy

authors： van Gelder CM,Vollebregt AA,Plug I,van der Ploeg AT,Reuser AJ

更新日期：2012-11-01 00:00:00

abstract：:Until recently, atorvastatin was known only as a new but more potent statin ('me too' drug) for lowering low-density lipoprotein cholesterol. In the last 2 years, data has become available on nearly 32,000 patients, in clinical settings ranging from primary prevention to acute coronary syndromes. These trials show the...

journal_title：Expert opinion on pharmacotherapy

authors： Ray KK,Cannon CP

更新日期：2005-06-01 00:00:00

abstract：:Desvenlafaxine (DESV) is a newer antidepressant, which inhibits serotonin-norepinephrine reuptake neurotransmission, similarly to venlafaxine, milnacipran and duloxetine. It was approved in February 2008 by the FDA for the treatment of major depressive disorder (MDD), based on well-controlled and adequately powered, l...

journal_title：Expert opinion on pharmacotherapy

authors： Pae CU

更新日期：2011-12-01 00:00:00